These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead

Three stocks—Moderna, Krystal Biotech, and AMD—have significantly outperformed the S&P 500 this year and are positioned for continued growth. Moderna is advancing toward approvals for its influenza and norovirus vaccines plus cancer vaccine candidates. Krystal Biotech's gene therapy Vyjuvek for rare skin disease is generating strong earnings with expansion opportunities. AMD is capitalizing on AI growth through its server CPU leadership and gaining market share from Intel.

06/18/2026, 1:30 AM • The Motley Fool

Krystal Biotech to Present at Upcoming Scientific Conferences

Krystal Biotech announced it will present on multiple gene therapy programs at scientific conferences in May and June 2026, including presentations on KB409/KB410 for primary ciliary dyskinesia at ASGCT, interim CORAL-1 trial results for KB407 in cystic fibrosis at ATS, and KB707 immunotherapy data at ASCO.

04/30/2026, 8:00 AM • GlobeNewswire

Is Vertex Pharmaceuticals' Empire in Trouble?

Vertex Pharmaceuticals faces potential competition from newer cystic fibrosis drugs like Krystal Biotech's KB407 gene therapy, which could work for all CF patients versus Vertex's limited mutation coverage. However, the company's core franchise appears safe through the late 2030s due to patent exclusivity, and Vertex is actively diversifying its pipeline with approvals in gene editing and other therapeutic areas.

04/16/2026, 3:26 PM • The Motley Fool

Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million

Redmile Group increased its stake in Nurix Therapeutics by 4.4 million shares worth $63.43 million, bringing its total position to 11.31% of its assets. Despite the stock being down 6.5% over the past year, the fund's conviction in the biotech company reflects confidence in its lead BTK degrader program entering a registrational trial with strong Phase 1 data showing 83% objective response rate.

02/22/2026, 1:12 PM • The Motley Fool

Stock Market Today, Feb. 18: ImmunityBio Soars After EU Approves ANKTIVA for Bladder Cancer

ImmunityBio stock surged 41.36% on Feb. 18, 2026, after the European Commission granted conditional marketing authorization for its Anktiva immunotherapy to treat bladder cancer. The approval expands access to over 30 new countries and positions the drug for accelerated sales growth. Despite the positive news, the stock remains volatile and heavily dependent on Anktiva's continued success.

02/18/2026, 5:17 PM • The Motley Fool

Soleus Adds a Significant Number of Celcuity Shares

Soleus Capital Management increased its stake in Celcuity by 629,398 shares, bringing its total holdings to over 1.8 million shares valued at $180.36 million. This purchase elevated Celcuity to Soleus's third-largest holding, representing 6.7% of the fund's AUM. The move signals bullish confidence in the clinical-stage biotech company, which has seen its stock surge 745% over the past year.

02/13/2026, 7:34 AM • The Motley Fool

Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

Krystal Biotech announced it will report Q4 and full year 2025 financial results on February 17, 2026, with preliminary 4Q 2025 VYJUVEK net revenue of $106-107 million. The company also received FDA RMAT designation for KB707 for advanced or metastatic non-small cell lung cancer treatment, demonstrating progress in its clinical pipeline.

02/10/2026, 8:00 AM • GlobeNewswire

Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Krystal Biotech reported preliminary 4Q 2025 VYJUVEK net revenue of $106-107 million and full-year 2025 revenue of $388-389 million. The company outlined an ambitious strategic vision to become a global leader in rare disease with plans to launch at least four marketed medicines by 2030, treating over 10,000 patients. The company maintains a strong balance sheet with $955 million in cash and investments, and expects combined non-GAAP R&D and SG&A expenses of $175-195 million in 2026.

01/11/2026, 1:00 PM • GlobeNewswire

Why a Fund Placed a $13 Million Bet on Ambarella Stock Before a 20% Post-Earnings Drop

S Squared Technology increased its Ambarella position by 35,000 shares (worth $4.8 million) in November, bringing total holdings to $12.7 million. The purchase preceded Ambarella's late-November earnings report, which triggered a 20% stock decline despite record revenue growth of 31% YoY and raised full-year guidance to 38%. The fund's timing suggests confidence in long-term fundamentals despite near-term margin concerns.

12/19/2025, 11:48 AM • The Motley Fool

Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound?

Connecticut-based fund Braidwell established a new $50.8 million stake in Acadia Pharmaceuticals, representing 2.1% of its reportable U.S. equity assets, as the company shows strong quarterly performance and potential for growth in neurological disorder treatments.

12/03/2025, 7:12 PM • The Motley Fool

Soleno Turns First Profit on $66 Million in Revenue — Is This Why One Investor Just Made an $87 Million Bet?

Soleno Therapeutics achieved its first profitable quarter with $66 million in revenue, attracting a significant $86.7 million investment from Connecticut-based fund Braidwell, which acquired 1.3 million shares in the biotechnology company.

12/03/2025, 7:02 PM • The Motley Fool

Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference

Krystal Biotech will participate in the 8th Annual Evercore Healthcare Conference on December 3, 2025, with CEO Krish S. Krishnan hosting a fireside chat and investor meetings. The company has generated $97.8 million in Q3 VYJUVEK revenue and launched the product in multiple countries.

11/26/2025, 8:00 AM • GlobeNewswire

Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label

The FDA approved a label update for VYJUVEK, expanding treatment eligibility for dystrophic epidermolysis bullosa (DEB) patients from birth and allowing patients and caregivers to apply the treatment at home with more flexible wound dressing management.

09/15/2025, 8:00 AM • GlobeNewswire

Quoin (QNRX) Q2 Loss Beats Estimates

Quoin Pharmaceuticals reported a net loss of $6.28 per share in Q2 2025, which exceeded analyst estimates. The company is developing QRX003, a topical lotion for Netherton Syndrome, and made significant clinical and regulatory progress while increasing R&D spending.

08/08/2025, 12:14 AM • The Motley Fool

Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté

Jeune Aesthetics reported positive Phase 1 study results for KB304, an investigational aesthetic therapy designed to deliver collagen and elastin to restore skin naturally, showing significant improvements in wrinkle appearance and skin quality.

07/24/2025, 8:00 AM • GlobeNewswire